Madrigal Pharmaceuticals Inc (MDGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Madrigal Pharmaceuticals Inc (Madrigal), formerly, Synta Pharmaceuticals Corp is a biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, MGL-3196 (orally administered), is a proprietary, liver-directed, selective thyroid hormone receptor beta, (THR-), agonist that can potentially be used for treating several disease with high unmet medical need. The company is developing MGL-3196 for non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia (FH). The company is also developing MGL-3745 (THR- agonist), a preclinical compound that has similar thyroid receptor selectivity to MGL-3196. Madrigal is also headquartered in West Conshohocken, Pennsylvania, the US.

Madrigal Pharmaceuticals Inc (MDGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Madrigal Pharma Raises USD3.37 Million in Venture Financing 12
Merger 13
Madrigal Pharma and Synta Pharma Merges 13
Licensing Agreements 15
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 15
PRCL Research Enters into Licensing Agreement with Synta Pharma 16
Equity Offering 17
Madrigal Pharma Plans to Raise USD200 Million in Public Offering of Securities 17
Madrigal Pharma Prices Public Offering of Shares for USD125 Million 18
Madrigal Pharma Plans to Raise up to USD5 Million in Public Offering of Shares 20
Madrigal Pharma Raises USD35 Million in Private Placement of Shares 21
Madrigal Pharma Raises USD6.1 Million in Public Offering of Shares 22
Synta Pharma Raises USD44.3 Million in Public Offering of Shares 23
Synta Pharma Raises USD5 Million in Private Placement Of Shares 25
Synta Pharma Completes Public Offering Of Shares For US$60.4 Million 26
Synta Pharma Completes Private Placement Of Shares For US$9.3 Million 28
Synta Pharma Completes Private Placement Of Common Stock For US$60 Million 29
Synta Pharma Completes Private Placement Of Shares For US$26 Million 31
Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For US$35 Million 33
Asset Transactions 35
Synta Pharma Sells its Drug Candidate, Elesclomol 35
Acquisition 36
Madrigal Pharma May Sell Itself 36
Madrigal Pharmaceuticals Inc - Key Competitors 37
Madrigal Pharmaceuticals Inc - Key Employees 38
Madrigal Pharmaceuticals Inc - Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
May 08, 2018: Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements 40
Mar 13, 2018: Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196 43
Nov 09, 2017: Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results 45
Aug 10, 2017: Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results 47
May 11, 2017: Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results 49
Apr 03, 2017: Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196 50
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List Of Tables


Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Madrigal Pharma Raises USD3.37 Million in Venture Financing 12
Madrigal Pharma and Synta Pharma Merges 13
Tarveda Therapeutics Enters into Licensing Agreement with Madrigal Pharma 15
PRCL Research Enters into Licensing Agreement with Synta Pharma 16
Madrigal Pharma Plans to Raise USD200 Million in Public Offering of Securities 17
Madrigal Pharma Prices Public Offering of Shares for USD125 Million 18
Madrigal Pharma Plans to Raise up to USD5 Million in Public Offering of Shares 20
Madrigal Pharma Raises USD35 Million in Private Placement of Shares 21
Madrigal Pharma Raises USD6.1 Million in Public Offering of Shares 22
Synta Pharma Raises USD44.3 Million in Public Offering of Shares 23
Synta Pharma Raises USD5 Million in Private Placement Of Shares 25
Synta Pharma Completes Public Offering Of Shares For US$60.4 Million 26
Synta Pharma Completes Private Placement Of Shares For US$9.3 Million 28
Synta Pharma Completes Private Placement Of Common Stock For US$60 Million 29
Synta Pharma Completes Private Placement Of Shares For US$26 Million 31
Synta Pharma Completes Over-allotment Option For Public Offering Of Common Stock For US$35 Million 33
Synta Pharma Sells its Drug Candidate, Elesclomol 35
Madrigal Pharma May Sell Itself 36
Madrigal Pharmaceuticals Inc, Key Competitors 37
Madrigal Pharmaceuticals Inc, Key Employees 38
Madrigal Pharmaceuticals Inc, Subsidiaries 39

List Of Figures


Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Madrigal Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Madrigal Pharmaceuticals Inc (MDGL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Madrigal Pharmaceuticals Inc (Madrigal), formerly, Synta Pharmaceuticals Corp is a biopharmaceutical company focused on the development and commercialization of novel therapeutic candidates for the treatment of liver, cardiovascular and metabolic

USD 250 View Report

Madrigal Pharmaceuticals Inc (MDGL) - Financial and Strategic SWOT Analysis Review

Madrigal Pharmaceuticals Inc (MDGL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

Aprogen pharmaceuticals Inc (003060) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Aprogen pharmaceuticals Inc (Aprogen), formerly Schnell Biopharmaceuticals Inc is a healthcare company that provides agents and antibiotics. The company offers pharmaceutical products such as amino acid infusion agents and antibiotics.

USD 250 View Report

Oncogenex Pharmaceuticals Inc (ACHV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Oncogenex Pharmaceuticals Inc (OncoGenex) formerly known as Sonus Pharmaceuticals Inc, is a drug discovery and development company that develops and commercializes therapies and mechaisms for addressing treatment resistance in cancer

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available